Loading the section…

OCUL: financial statements from SEC — TradeAlmanac

OCUL

Ocular Therapeutix, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	11M	15M	13M	11M	15M	16M
Cost of revenue	1M	2M	2M	1M	2M	2M
Research and development	66M	52M	51M	43M	37M	29M
Selling, general and administrative	20M	16M	14M	16M	12M	20M
Operating expenses	104M	83M	81M	75M	61M	60M
Operating income	−93M	−69M	−68M	−64M	−46M	−44M
Net income	−89M	−69M	−68M	−64M	−36M	−44M
Earnings per share	−0.40	−0.38	−0.39	−0.38	−0.22	−0.26
Earnings per share, diluted	−0.40	−0.38	−0.39	−0.38	−0.22	−0.26
Weighted average shares	224M	184M	173M	169M	167M	166M
Weighted average shares, diluted	224M	184M	173M	169M	167M	166M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	667M	737M	345M	391M	350M	392M	427M	460M
Receivables	24M	31M	31M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−66M	−45M
Depreciation and amortisation	1M	981,000
Share-based compensation	16M	10M
Capital expenditure	5M	2M
Investing cash flow	−5M	−2M
Financing cash flow	294,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator